The FDA’s approval of several anti-Aβ drugs (Aducanumab and Lecanemab) for clinical use provides significant achievements for both basic research and clinical investigations on AD [5].The pathological hallmarks of AD in the brain are extracellular Aβ plaques, hyperphosphorylated tau-formed neurofibrillary tangles, and significant neuron loss [6,7]. Here, MAPT is linked to Alzheimer disease.